Heron Therapeutics, Inc.

Thank you for standing by. My name is Hermione and I will be your conference operator today. At this time, I would like to welcome everyone to Hairline Therapeutics Q2 2024 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw a question, press star 1 again. I would now like to turn the call over to Melissa Gile, Executive Director, Legal. Please go ahead.

Thank you, operator, and good afternoon, everyone. Thank you for joining us on the Heron Therapeutics conference call this afternoon to discuss the company's financial results for the quarter ended June 30th, 2024. With me today from Heron are Craig Pollard, Chief Executive Officer, Ira Duarte, Executive Vice President, Chief Financial Officer, Bill Forbes, Executive Vice President, Chief Development Officer, and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call. Before we begin, let me remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and future performance, all of which constitute forward-looking statements for the purposes of the State Harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statement. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the State Harbor Statement in today's press release and in Heron's public periodic filing with the FTC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. And with that, I would now like to turn it over to Craig Pollard, Chief Executive Officer of Charon.

Thanks, Melissa. Good morning, everyone, and welcome to the Heron Therapeutics Second Quarter 2024 Earnings Call. Today, we are pleased to update you on our latest achievements for the second quarter, which includes a narrowing of our financial guidance and a view into our financial performance, Discussion of our product performance. Progression of the vial, access needle, or van towards our September 23rd producer date. The publishing of the long-awaited no-paying act, which includes NLF. And last, an update on the billing and training of our partners at Crosswind.